Primaquine radical cure of Plasmodium vivax malaria: a risk benefit analysis

Dr Robert Commons

2016 RACP NHMRC Awards for Excellence - Kincaid-Smith Scholarship

31 December 2018

Robert Commons / Professor Richard Price

Menzies School of Health Research

1 February 2016

1 February 2019

Recent intensification of malaria control efforts in Asia and South America has significantly reduced the worldwide burden of falciparum malaria, but Plasmodium vivax is more difficult to control. Vivax malaria causes significant morbidity with over 100 million clinical cases yearly. Without increased research into P. vivax the aim of malaria eradication is unlikely to be achieved.

Unlike P. falciparum, P. vivax can relapse due to dormant liver stage hypnozoites. Successful control and ultimate elimination of P. vivax requires prevention of recurrent infections by safe and effective radical cure, combining drugs active against both the blood and liver stages of the parasite. Primaquine is the only widely available hypnozoiticide (liver stage drug), but can cause severe drug-induced haemolysis in glucose-6- phosphate dehydrogenase (G6PD) deficient patients.

The risk of serious haemolysis associated with G6PD deficiency makes clinicians reluctant to prescribe primaquine without prior testing, which is often unavailable. When primaquine is prescribed, patient adherence to the standard 14 day regimen is poor, resulting in a high risk of treatment failure. Despite 60 years of clinical use, knowledge of primaquine safety, and efficacy is rudimentary. Effective radical cure is the key to vivax malaria elimination, but the clinical and public health consequences of primaquine demand a rigorous understanding of the risks and benefits to inform use.

This thesis aims to improve understanding of the risks and benefits of giving primaquine radical cure to cure vivax. Through a series of systematic reviews and pooling large numbers of patient data from existing malaria trials, the thesis investigates the risks for P. vivax recurrence including the effect of drug dose and primaquine use, quantifies the haematological risks of acute and recurrent vivax malaria including primaquine-induced haemolysis and investigates potential
benefits of primaquine radical cure in patients from co-endemic regions with P. falciparum infection.

PROJECT AIMS / OBJECTIVES

The aim of this project is to provide evidence to minimise Plasmodium vivax attributable anaemia, through safe and effective drug regimens, which target both the blood and liver stages of the malarial parasite. The ultimate objective is to reduce P. vivax attributable morbidity and mortality and accelerate malaria elimination.

The project addresses the following objectives through a series of two systematic reviews of antimalarial efficacy studies and three individual pooled meta-analyses:

i) What are the risk factors for P. vivax recurrence and relapse with or without primaquine?

ii) What are the haematological consequences of acute and recurrent vivax malaria in different endemic locations?

iii) How does the risk of primaquine-induced haemolysis vary between individuals?

iv) To what degree does drug induced haemolysis vary with the dose of primaquine?

v) What benefit does primaquine have in preventing P. vivax infection after P. falciparum infection?

SIGNIFICANCE AND OUTCOMES

Outcomes from this project will inform assessment of the risks and benefits of primaquine radical cure of P. vivax malaria for policymakers and clinicians. The finding that chloroquine dose effects risk of recurrence in children younger than five years will be discussed at the WHO’s malaria expert advisory committee to consider changing the dose of chloroquine in response.

Evidence of the safety and benefits of primaquine will assist policy-makers as they review how to most rapidly eliminate malaria. These results will also be important for international and national policymakers and clinicians to inform the integration of new diagnostics tests for G6PD deficiency and the new hypnozoitocidal agent tafenoquine into management of P. vivax.

Demonstration of the high risk of vivax parasitaemia following falciparum infection highlights the potential for universal radical cure to be considered in all patients with uncomplicated malaria in some co-endemic regions. To fully inform policy-makers, additional investigation will be required, including a pooled analysis of individual patient data which is currently being undertaken to identify the patients and regions that would benefit most from this policy.

Future research is also planned to identify the benefit of primaquine dose over 6 to 12 months, to assess the effect of cumulative recurrences on haemoglobin and to better understand the risk of anaemia in G6PD deficiency.

PUBLICATIONS / PRESENTATIONS

Peer-Reviewed Papers


Book Chapters

Conference Abstracts (oral)
1. Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, Sibley CH, Guerin PJ, Price RN, Universal radical cure of malaria, 1st Malaria World Congress, Melbourne, 2018
2. Commons RJ, on behalf of the WWARN Vivax Study Group, The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: an individual patient pooled analysis, ASID ASM, Gold Coast, 2018

Conference Abstracts (poster)
1. Commons RJ, on behalf of the WWARN Vivax Study Group, The effect of chloroquine dose and primaquine on P. vivax recurrence: an individual patient pooled analysis, American Society of Tropical Medicine and Hygiene, New Orleans, 2018
2. Commons RJ, on behalf of the WWARN Vivax Study Group, The haematological response following chloroquine treatment of Plasmodium vivax with or without primaquine: a pooled analysis of individual patient data, American Society of Tropical Medicine and Hygiene, New Orleans and 1st Malaria World Congress, Melbourne, 2018
3. Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, Sibley CH, Guerin PJ, Price RN, The risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis, American Society of Tropical Medicine and Hygiene, New Orleans; 1st Malaria World Congress, Melbourne; and ASID ASM, Gold Coast, 2018
4. Commons RJ, on behalf of the WWARN Vivax Study Group, The haematological profile following treatment of Plasmodium vivax: a pooled analysis of individual patient data, International Conference on Plasmodium vivax Research, Manaus, Brazil, 2017
5. Commons RJ, on behalf of the WWARN Vivax Study Group, The effect of dose on the antimalarial efficacy of chloroquine for Plasmodium vivax: a pooled analysis of individual patient data, International Conference on Plasmodium vivax Research, Manaus, Brazil, 2017
Invited Presentations

1. The effect of chloroquine dose and primaquine Plasmodium vivax recurrence: an individual patient pooled analysis, 1st Malaria World Congress, Melbourne, 2018

2. Workshop on Conducting Clinical Trials, International Conference on Plasmodium vivax Research, Manaus, Brazil, 2017